Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen: Aug 19, 2008

Asuragen this week launched Signature NPM1 Mutations, a multiplex, reverse-transcription PCR assay that enables the combined detection of mutations A, B, and D in exon 12 of the nucleophosmin (NPM1) gene.
According to Asuragen, the assay is designed to detect NPM1 mutant transcripts in total RNA isolated from cell line, whole blood, and bone marrow specimens. NPM1 has been reported to be one of the most commonly mutated genes in acute myeloid leukemia.

Signature NPM1 Mutations is made available on the Luminex 100 IS or 200 System using a liquid bead array method. According to the company, the liquid bead array format provides “comprehensive information in a single well, providing efficiency and cost benefits to the laboratory.”

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.